Pasithea Therapeutics Corp.(KTTA)

Biotechnology · Miami Beach, FL

$0.45-0.00 (-1.06%)

Delayed quote: Oct 6, 2026, 11:21 AM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T15:27:33.748Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:27:33.748Z.

Quote observation: 2026-10-06T15:21:42.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 15,039,842
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 45,663,782,000
TTM free cash flow · period ending 2026-06-30: -17,781,592

FMP input reference: b407bf9ab9426f7f8731c51b1e955f2cfcbe23f9f3e819a9868889fb687bb4da

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KTTA EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

KTTA Competitors' EV/FCF Ratio

KTTA

Pasithea Therapeutics Corp.

Current

Market Cap

$15.04M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KPTI

Karyopharm Therapeutics Inc.

vs KTTA

Market Cap

$15.03M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COCP

Cocrystal Pharma, Inc.

vs KTTA

Market Cap

$15.58M

EV/FCF Ratio

N/A

TTM Avg

97.85x

3Y Avg

97.85x

5Y Avg

97.85x

OBX

Obsidian Therapeutics Inc.

vs KTTA

Market Cap

$14.44M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALLR

Allarity Therapeutics, Inc.

vs KTTA

Market Cap

$15.75M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLSM

Pulsenmore Ltd. Ordinary Shares

vs KTTA

Market Cap

$14.24M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTXR

Citius Pharmaceuticals, Inc.

vs KTTA

Market Cap

$14.02M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BCDA

BioCardia, Inc.

vs KTTA

Market Cap

$16.15M

EV/FCF Ratio

N/A

TTM Avg

79.94x

3Y Avg

79.62x

5Y Avg

79.62x

PASG

Passage Bio, Inc.

vs KTTA

Market Cap

$13.78M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INAB

IN8bio, Inc.

vs KTTA

Market Cap

$13.71M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Pasithea Therapeutics Corp. (KTTA)	$15.04M	N/A	N/A	N/A	N/A
Karyopharm Therapeutics Inc. (KPTI)vs ›	$15.03M	N/A	N/A	N/A	N/A
Cocrystal Pharma, Inc. (COCP)vs ›	$15.58M	N/A	97.85x	97.85x	97.85x
Obsidian Therapeutics Inc. (OBX)vs ›	$14.44M	N/A	N/A	N/A	N/A
Allarity Therapeutics, Inc. (ALLR)vs ›	$15.75M	N/A	N/A	N/A	N/A
Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›	$14.24M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$14.02M	N/A	N/A	N/A	N/A
BioCardia, Inc. (BCDA)vs ›	$16.15M	N/A	79.94x	79.62x	79.62x
Passage Bio, Inc. (PASG)vs ›	$13.78M	N/A	N/A	N/A	N/A
IN8bio, Inc. (INAB)vs ›	$13.71M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

KTTA EV/FCF Ratio Metrics

KTTA Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics